LGNXZ — LIGAND PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 886163 ·
Last close
$0.00
Market Cap
—
52W High
$0.00
52W Low
$0.00
ADV30
10,000
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 51,812,000 | 43,554,000 | 3,143,000 | -7,172,000 | 941,774,000 | 72,307,000 | 111,335,000 |
| Dec 2023 | 32,868,000 | 24,630,000 | 3,078,000 | -10,273,000 | 787,216,000 | 22,954,000 | 86,303,000 |
| Dec 2022 | 59,221,000 | 50,653,000 | 12,341,000 | 404,000 | 762,668,000 | 45,006,000 | 165,183,000 |
| Dec 2021 | 64,835,000 | 53,008,000 | 15,706,000 | 13,723,000 | 1,297,590,000 | 19,522,000 | 476,431,000 |
Yahoo Snapshot (yfinance, live)
Total Revenue
$274,476,000
EBITDA
$134,447,008
Free Cash Flow
$142,107,376
Enterprise Value
—
Total Cash
$779,404,992
Total Debt
$451,976,992
Shares Out
—
Trailing EPS
—
Book Value
$49.79
ROE
17.1%
ROA
5.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 10y)
Revenues vs Net Income (last 10y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 131,314,000 | 11,942,000 | 52,154,000 | 941,774,000 | 111,335,000 | — | — |
| Dec 2023 | 196,245,000 | 3,037,000 | -33,361,000 | 787,216,000 | 86,303,000 | — | — |
| Dec 2022 | 241,544,000 | 103,851,000 | 57,138,000 | 762,668,000 | 165,183,000 | — | — |
| Dec 2021 | 46,592,000 | -10,144,000 | 18,107,000 | 1,297,590,000 | 476,431,000 | — | — |
| Dec 2020 | 120,282,000 | 807,076,000 | 629,302,000 | 1,362,285,000 | 652,760,000 | — | — |
| Dec 2019 | 43,484,000 | 13,746,000 | 666,337,000 | 1,494,915,000 | 727,683,000 | — | — |
| Dec 2018 | 56,157,000 | 37,041,000 | 45,279,000 | 1,260,803,000 | 699,889,000 | — | — |
| Dec 2017 | 56,157,000 | 37,041,000 | 45,279,000 | 671,021,000 | 252,374,000 | — | — |
| Dec 2016 | 29,648,000 | 15,096,000 | 6,608,000 | 601,585,000 | 230,732,000 | — | — |
| Dec 2015 | 14,602,000 | 3,349,000 | 754,000 | 503,061,000 | 226,151,000 | — | — |
TTM Snapshot
Revenues TTM
$169,360,000
NetIncome TTM
$-34,890,000
OpCashFlow TTM
$0
Assets (Latest)
$941,774,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.02T | $1148.84 | — |
| JNJ | JOHNSON & JOHNSON | $617.78B | $256.35 | — |
| ABBV | AbbVie Inc. | $443.36B | $250.94 | — |
| MRK | Merck & Co., Inc. | $321.57B | $130.20 | — |
| NVSEF | NOVARTIS AG | $301.30B | $158.52 | — |
News headlines (Yahoo Finance, 1h cache)
This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026
2026-07-27 18:09 · Yahoo
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-23 11:00 · Yahoo
Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings
2026-07-16 23:17 · Yahoo
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
2026-07-14 15:57 · Yahoo
XOMA Royalty Announces Closing of Its Acquisition by Ligand
2026-07-14 13:00 · Yahoo
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
2026-07-14 13:00 · Yahoo
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
2026-07-14 12:15 · Yahoo
Agenus shares surge as company secures up to $340M to advance colon cancer trial
2026-07-13 16:53 · Yahoo
3 Overlooked Stocks Positioned for the Next Market Rotation
2026-07-13 12:35 · Yahoo
Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN)
2026-07-13 12:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.